Sanofi has received $0.64 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 3 Financial Advisor in the Stock Trading Firms. Among 3 Analysts, Bottom line EPS Estimate for the current quarter is $0.63 while the top line estimate is $0.67 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -10.65%.
Sanofi reported better than expected with a surprise EPS of 16.28% or $0.14 during its most recent quarterly earnings. The Actual EPS was $1 compared to the Estimated EPS of $0.86.
Sanofi has a Price to Earnings ratio of 12.5 for the trailing twelve month period. The price to book ratio of the company for the most recent quarter is 1.68. For the Most Recent Fiscal Year, Sanofi has a price to cash ratio of 8.11. For the Trailing twelve month period, company showed a Net Profit Margin of 12.22% and Return on Equity of the stock is 19.56%.
In the last quarter, Sanofi reported Annual Earnings of $1. Based on the filings, last years Annual Earnings was, $3.11. In the last Quarter, SNY reported a surprise Earnings per Share of 16.28% . The consensus estimate for current quarter is $0.64 and for the current fiscal year, the estimate is $3.01. For the Next fiscal year, the estimate is $2.96 based on the consensus.
Sanofi (NYSE:SNY) : On Tuesday heightened volatility was witnessed in Sanofi (NYSE:SNY) which led to swings in the share price. The stock opened for trading at $39.94 and hit $40.81 on the upside , eventually ending the session at $40.78, with a gain of 1.95% or 0.78 points. The heightened volatility saw the trading volume jump to 2,496,444 shares. The 52-week high of the share price is $44.5 and the company has a market cap of $104,976 million. The 52-week low of the share price is at $36.8101 .
Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.